Literature DB >> 28873047

Gadolinium Retention in the Rat Brain: Assessment of the Amounts of Insoluble Gadolinium-containing Species and Intact Gadolinium Complexes after Repeated Administration of Gadolinium-based Contrast Agents.

Eliana Gianolio1, Paola Bardini1, Francesca Arena1, Rachele Stefania1, Enza Di Gregorio1, Rebecca Iani1, Silvio Aime1.   

Abstract

Purpose To evaluate the speciation of gadolinium-containing species after multiple administrations of the gadolinium-based contrast agents (GBCAs) gadodiamide and gadoteridol and to quantify the amount of intact gadolinium complexes and insoluble gadolinium-containing species. Materials and Methods A total dose of 13.2 mmol per kilogram of body weight of each GBCA was administered in healthy Wistar rats over a period of 8 weeks. Three days after the final administration, rats were sacrificed, and the brains were excised and divided into three portions. Each portion of brain homogenate was divided into two parts, one for determination of the total gadolinium concentration with inductively coupled plasma mass spectrometry and one for determination of the amount of intact GBCA and gadolinium-containing insoluble species. Relaxometric measurements of gadodiamide and gadolinium trichloride in the presence of polysialic acid were also performed. Results The mean total gadolinium concentrations for gadodiamide and gadoteridol, respectively, were 0.317 μg/g ± 0.060 (standard deviation) and 0.048 μg/g ± 0.004 in the cortex, 0.418 μg/g ± 0.078 and 0.051 μg/g ± 0.009 in the subcortical brain, and 0.781 μg/g ± 0.079 and 0.061 μg/g ± 0.012 in the cerebellum. Gadoteridol comprised 100% of the gadolinium species found in rats treated with gadoteridol. In rats treated with gadodiamide, the largest part of gadolinium retained in brain tissue was insoluble species. In the cerebellum, the amount of intact gadodiamide accounts for 18.2% ± 10.6 of the total gadolinium found therein. The mass balance found for gadolinium implies the occurrence of other soluble gadolinium-containing species (approximately 30%). The relaxivity of the gadolinium polysialic acid species formed in vitro was 97.8 mM/sec at 1.5 T and 298 K. Conclusion Gadoteridol was far less retained, and the entire detected gadolinium was intact soluble GBCA, while gadodiamide yielded both soluble and insoluble gadolinium-containing species, with insoluble species dominating. © RSNA, 2017 Online supplemental material is available for this article.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28873047     DOI: 10.1148/radiol.2017162857

Source DB:  PubMed          Journal:  Radiology        ISSN: 0033-8419            Impact factor:   11.105


  31 in total

Review 1.  The biological fate of gadolinium-based MRI contrast agents: a call to action for bioinorganic chemists.

Authors:  Mariane Le Fur; Peter Caravan
Journal:  Metallomics       Date:  2019-02-20       Impact factor: 4.526

2.  Nonhomogeneous Gadolinium Retention in the Cerebral Cortex after Intravenous Administration of Gadolinium-based Contrast Agent in Rats and Humans.

Authors:  Olga Minaeva; Ning Hua; Erich S Franz; Nicola Lupoli; Asim Z Mian; Chad W Farris; Audrey M Hildebrandt; Patrick T Kiernan; Laney E Evers; Allison D Griffin; Xiuping Liu; Sarah E Chancellor; Katharine J Babcock; Juliet A Moncaster; Hernan Jara; Victor E Alvarez; Bertrand R Huber; Ali Guermazi; Lawrence L Latour; Ann C McKee; Jorge A Soto; Stephan W Anderson; Lee E Goldstein
Journal:  Radiology       Date:  2019-11-26       Impact factor: 11.105

Review 3.  Gadolinium-based contrast agents - review of recent literature on magnetic resonance imaging signal intensity changes and tissue deposits, with emphasis on pediatric patients.

Authors:  Einat Blumfield; David W Swenson; Ramesh S Iyer; A Luana Stanescu
Journal:  Pediatr Radiol       Date:  2019-03-29

4.  Comparison of the Relaxivities of Macrocyclic Gadolinium-Based Contrast Agents in Human Plasma at 1.5, 3, and 7 T, and Blood at 3 T.

Authors:  Pavol Szomolanyi; Martin Rohrer; Thomas Frenzel; Iris M Noebauer-Huhmann; Gregor Jost; Jan Endrikat; Siegfried Trattnig; Hubertus Pietsch
Journal:  Invest Radiol       Date:  2019-09       Impact factor: 6.016

Review 5.  Standardized assessment of the signal intensity increase on unenhanced T1-weighted images in the brain: the European Gadolinium Retention Evaluation Consortium (GREC) Task Force position statement.

Authors:  Carlo C Quattrocchi; Joana Ramalho; Aart J van der Molen; Àlex Rovira; Alexander Radbruch
Journal:  Eur Radiol       Date:  2018-11-09       Impact factor: 5.315

Review 6.  Gadolinium-Based Contrast Agent-Related Toxicities.

Authors:  Luca Pasquini; Antonio Napolitano; Emiliano Visconti; Daniela Longo; Andrea Romano; Paolo Tomà; Maria Camilla Rossi Espagnet
Journal:  CNS Drugs       Date:  2018-03       Impact factor: 5.749

7.  Impact of chelation timing on gadolinium deposition in rats after contrast administration.

Authors:  John P Prybylski; Carla Coste Sanchez; Michael Jay
Journal:  Magn Reson Imaging       Date:  2018-10-12       Impact factor: 2.546

Review 8.  Gadolinium deposition and the potential for toxicological sequelae - A literature review of issues surrounding gadolinium-based contrast agents.

Authors:  Kerry A Layne; Paul I Dargan; John R H Archer; David M Wood
Journal:  Br J Clin Pharmacol       Date:  2018-08-17       Impact factor: 4.335

Review 9.  Chemistry of MRI Contrast Agents: Current Challenges and New Frontiers.

Authors:  Jessica Wahsner; Eric M Gale; Aurora Rodríguez-Rodríguez; Peter Caravan
Journal:  Chem Rev       Date:  2018-10-16       Impact factor: 60.622

10.  The Effects of Gadolinium-Based Contrast Agents on the Cerebellum: from Basic Research to Neurological Practice and from Pregnancy to Adulthood.

Authors:  Winda Ariyani; Miski Aghnia Khairinisa; Gaetano Perrotta; Mario Manto; Noriyuki Koibuchi
Journal:  Cerebellum       Date:  2018-06       Impact factor: 3.847

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.